GlassScriptPhysician profile
Mark L Donaldson
NPI 1982662102
$4,990.93
in general payments reported to CMS, 2019-2025
28 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $230 · 2021: $142 · 2022: $488 · 2023: $588 · 2024: $2,357 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,750 · Food and Beverage: $1,495 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,750.00 |
| Food and Beverage | $1,494.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Premier Dental Products Company | $1,750.00 | 2024 | None |
| Abbvie INC. | $651.80 | 2019-2025 | Skyrizi, Rinvoq, Qulipta |
| Novartis Pharmaceuticals Corporation | $383.89 | 2019-2025 | |
| Pfizer INC. | $366.60 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $189.14 | 2019-2020 | |
| Janssen Biotech, INC. | $172.34 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $166.33 | 2022-2025 | Libtayo |
| Amgen INC. | $145.31 | 2019-2023 | Otezla |
| Genzyme Corporation | $144.97 | 2019-2025 | |
| Lilly USA, LLC | $139.30 | 2019-2024 | Olumiant, Taltz |
| Ucb, INC. | $118.78 | 2019-2023 | Cimzia |
| Sun Pharmaceutical Industries INC. | $100.92 | 2019-2023 | Ilumya |
| Galderma Laboratories, L.P. | $86.26 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $86.00 | 2022-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $78.23 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.75 | 2022-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $51.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $46.14 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.00 | 2019 | |
| Genentech USA, INC. | $34.40 | 2019 | |
| Organon LLC | $27.78 | 2025 | Vtama |
| Incyte Corporation | $22.66 | 2025 | Opzelura |
| Ani Pharmaceuticals, INC. | $22.48 | 2022 | |
| Sandoz INC. | $21.39 | 2023 | Hyrimoz |
| Dermavant Sciences, INC. | $17.92 | 2023 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $16.96 | 2019 | |
| Boston Scientific Corporation | $14.97 | 2023 | |
| Tactile Systems Technology INC | $13.79 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Donaldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.